GLP-1 & Incretin Science

Hy's Law: How Trials Decide a Drug Hurt the Liver

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Trials use a combination rule usually called Hy's Law: transaminases above three times the upper limit of normal, total bilirubin above twice the upper limit, without an alternative explanation such as biliary obstruction. Enzyme elevation alone does not meet it.

Key facts

Named after
Hyman Zimmerman
Component 1
ALT or AST above 3× upper limit of normal
Component 2
Total bilirubin above 2× upper limit
Component 3
No alternative cause; ALP not markedly raised
Significance
Predicts risk of severe outcome
Enzyme rise alone
Common, usually not meaningful

Why one measurement is not enough

Transaminases leak from damaged liver cells, so a rise indicates injury to hepatocytes. But mild rises are extremely common, occur with many drugs and with none, and usually resolve without consequence. A threshold on enzymes alone would flag enormous numbers of clinically irrelevant events.

What bilirubin adds

Function rather than damage. Bilirubin is cleared by the liver, so a rise means the organ's capacity to do its job has been compromised, not merely that some cells were injured. Damage plus loss of function is a more serious combination than damage alone, and requiring both is what makes the rule discriminating.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why the exclusion matters

Bilirubin also rises when bile cannot drain (a gallstone, a stricture, a tumour). That is obstruction rather than drug toxicity. Checking that alkaline phosphatase is not disproportionately elevated distinguishes hepatocellular injury from a blocked biliary tree, and without that step the rule would capture the wrong patients.

Why the combination is taken so seriously

Zimmerman's observation was that patients meeting these criteria had a substantial risk of progressing to liver failure or death. That empirical association is what gives the rule its weight. It is a pattern that predicted severe outcomes, not an arbitrary regulatory threshold.

The detection problem this creates

Idiosyncratic drug-induced liver injury is rare, often around one in several thousand exposures or rarer. A Phase 2b trial of a few hundred participants is simply too small to observe such an event reliably, so a clean liver result at that stage is reassuring but not conclusive. This is why the danuglipron case (one participant) was treated as significant despite being a single observation.

How to read a safety statement

No cases of drug-induced liver injury is a specific claim about this rule being met by nobody. Liver enzyme elevations were in line with approved agents is a quite different and much weaker statement. Both appeared in the recent oral GLP-1 literature, attached to different compounds, and the difference between them is the whole story.

Quick reference

FindingWhat it meansWeight
ALT/AST raised onlyHepatocyte damageCommon, often unimportant
Bilirubin raised tooFunction impairedSerious in combination
ALP also highSuggests obstructionPoints away from drug injury

Frequently asked questions

What is Hy's Law?

Transaminases above 3× the upper limit of normal, total bilirubin above 2×, with no alternative explanation such as biliary obstruction.

Why does bilirubin matter so much?

It reflects impaired function rather than mere cell damage. Damage plus loss of function predicts severe outcomes; damage alone usually does not.

Can a Phase 2b trial rule out liver injury?

No. Idiosyncratic injury may occur in one in several thousand exposures, which a few hundred participants cannot exclude.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.